Advertisement


Laurie Helen Sehn, MD, MPH, on FL and DLBCL: Results From a Treatment Trial

2018 ASCO Annual Meeting

Advertisement

Laurie Helen Sehn, MD, MPH, of the British Columbia Cancer Centre for Lymphoid Cancer, discusses phase II study findings on polatuzumab vedotin with bendamustine and rituximab in relapsed or refractory follicular lymphoma and diffuse large B-cell lymphoma (Abstract 7507).



Related Videos

Geriatric Oncology

Supriya G. Mohile, MD, on Communicating With Older Cancer Patients: Results From a Community Trial

Supriya G. Mohile, MD, of the University of Rochester Medical Center, discusses study findings on ways to improve communication with older cancer patients using geriatric assessment (Abstract LBA10003).

Survivorship
Integrative Oncology
Symptom Management

Jun J. Mao, MD, MSCE, on Insomnia in Cancer Survivors: Trial Results

Jun J. Mao, MD, MSCE, of Memorial Sloan Kettering Cancer Center, discusses study findings on the effect of acupuncture vs cognitive behavior therapy in cancer survivors experiencing insomnia (Abstract 10001).

Breast Cancer

Gabriel N. Hortobagyi, MD, on Breast Cancer Staging: New and Important Changes

Gabriel N. Hortobagyi, MD, of The University of Texas MD Anderson Cancer Center, discusses the 8th edition of the TNM staging system, which includes prognostic stage groups based on clinical and pathologic factors combined with grade and hormone and HER2 status.

Kidney Cancer

Arnaud Méjean, MD, PhD, on RCC: Results From the Carmena Trial

Arnaud Méjean, MD, PhD, of the Hôpital Européen Georges Pompidou, discusses his study’s potentially practice-changing finding that nephrectomy is no longer the standard of care for patients with metastatic renal cell carcinoma (Abstract LBA3).

Breast Cancer

Rebecca A. Dent, MD, on Triple-Negative Breast Cancer: Results From the LOTUS Trial

Rebecca A. Dent, MD, of the National Cancer Centre Singapore, discusses phase II study findings on first-line ipatasertib plus paclitaxel for locally advanced/metastatic triple-negative breast cancer (Abstract 1008).

Advertisement

Advertisement




Advertisement